$CATX received 5 mentions from 2 distinct FinTwit voices over a 12-month period, with the first mention appearing on 2025-10-22 and the most recent on 2026-04-05. The biotech-focused account @jacobplieth generated 4 of the 5 mentions, while @investmentguru_ contributed 1 mention. The discussion centered on $CATX's precision oncology approach using alpha-particle therapy for cancer treatment, with one voice noting the stock declined 10% on 2026-01-30 and another suggesting potential competitive advantages following a discontinued rival therapy.